Allergan’s new antipsychotic faces generic competition

Actavis Allergan merger

Allergan partnered with Gedeon Richeter to producer Vraylar, a new antipsychotic that is used to treat bipolar disorder and schizophrenia in adults. The drug recently received FDA approval. However, it is expected to face stiff generic competition that could depress sales. Generic versions of Risperdal, Seroquel, Abilify and Zyprexa are expected to curb Vraylar sales.

Read the source article at Pharma News

About the Author

Related Posts

Leave a Reply